Xenobiotic Pathway Gene Polymorphisms Associated with Gastric Cancer in High Risk Mizo-Mongoloid Population, Northeast India

Helicobacter ◽  
2016 ◽  
Vol 21 (6) ◽  
pp. 523-535 ◽  
Author(s):  
Souvik Ghatak ◽  
Ravi Prakash Yadav ◽  
Freda Lalrohlui ◽  
Payel Chakraborty ◽  
Soumee Ghosh ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Gene Polymorphisms ◽  
Northeast India ◽  
Pathway Gene ◽  
Mongoloid Population

GSTT1 andGSTM1 gene polymorphisms and gastric cancer in a high-risk italian population

2005 ◽  
Vol 115 (2) ◽  
pp. 284-289 ◽  
Author(s):  
Domenico Palli ◽  
Calogero Saieva ◽  
Simonetta Gemma ◽  
Giovanna Masala ◽  
Maria Jesus Gomez-Miguel ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Gene Polymorphisms ◽  
Italian Population

Interleukin-1 Gene Polymorphisms and Gastric Cancer Risk in a High-Risk Italian Population

2005 ◽  
Vol 100 (9) ◽  
pp. 1941-1948 ◽  
Author(s):  
D. Palli ◽  
C. Saieva ◽  
I. Luzzi ◽  
G. Masala ◽  
S. Topa ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Cancer Risk ◽  
Gene Polymorphisms ◽  
Interleukin 1 ◽  
Italian Population ◽  
Gastric Cancer Risk

Association of DNA repair and xenobiotic pathway gene polymorphisms with genetic susceptibility to gastric cancer patients in West Bengal, India

Tumor Biology ◽  
2016 ◽  
Vol 37 (7) ◽  
pp. 9139-9149 ◽  
Author(s):  
Soumee Ghosh ◽  
Sudakshina Ghosh ◽  
Biswabandhu Bankura ◽  
Makhan Lal Saha ◽  
Suvendu Maji ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Dna Repair ◽  
Genetic Susceptibility ◽  
Cancer Patients ◽  
Gene Polymorphisms ◽  
West Bengal ◽  
Pathway Gene ◽  
Gastric Cancer Patients

scholarly journals Gene Polymorphisms of Micrornas in Helicobacter pylori-Induced High Risk Atrophic Gastritis and Gastric Cancer

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e87467 ◽  
Author(s):  
Juozas Kupcinskas ◽  
Thomas Wex ◽  
Alexander Link ◽  
Marcis Leja ◽  
Indre Bruzaite ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Helicobacter Pylori ◽  
High Risk ◽  
Atrophic Gastritis ◽  
Gene Polymorphisms

Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 4026-4026 ◽  
Author(s):  
Takeru Wakatsuki ◽  
Wu Zhang ◽  
Dongyun Yang ◽  
Fotios Loupakis ◽  
Mizutomo Azuma ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Gene Polymorphisms ◽  
Predictive Marker ◽  
Training Set ◽  
Exact Test ◽  
Direct Dna Sequencing ◽  
Predictive Gene ◽  
Pathway Gene ◽  
Pan American ◽  
Validation Set

4026 Background: AVAGAST showed regional bevacizumab (Bev) efficacy difference (RBED), namely, Asian (Asi) patients (pts) with gastric cancer (GC) had no benefit whereas European and Pan-American patients had more benefit from Bev. Recently, germline gene polymorphisms in angiogenesis have been recognized as predictive marker for Bev efficacy. Allele frequency (AF) in gene polymorphisms may vary depending on ethnicity. We tested the hypothesis whether angiogenic pathway gene polymorphisms may have different AF among Asi, Caucasian (Cau), and Hispanic (Hisp) in GC and this disparity may explain RBED. Methods: Three-hundred pts [Japanese (Jap), Cau, and Hisp, 100 from each race] with histopathologically confirmed GC were collected from Japan, USA, Austria, and Italy between 1991 and 2011. These pts were divided into 2 groups as training set (n=50) and validation set (n=50) in each race. Seven functional gene polymorphisms previously reported as predictive marker were selected. All samples were analyzed using PCR-based direct DNA- sequencing. Fisher's exact test was used to compare the distribution of AF among races. Results: Significant disparate distributions in favorable AF for Bev were shown among races in Table. Jap GC pts had significant lower AF of 5 predictive gene polymorphisms in training set, and among these 5, three predictive gene polymorphisms were also validated. Conclusions: Our preliminary results showed significant disparate AF distributions in predictive gene polymorphisms for Bev, and these disparities may explain RBED in AVAGAST. Further investigation is warranted to elucidate RBED. [Table: see text]

scholarly journals Accuracy of upper endoscopies with random biopsies to identify patients with gastric premalignant lesions who can safely be exempt from surveillance

2021 ◽  
Vol 24 (3) ◽  
pp. 680-690
Author(s):  
Michiel C. Mommersteeg ◽  
Stella A. V. Nieuwenburg ◽  
Wouter J. den Hollander ◽  
Lisanne Holster ◽  
Caroline M. den Hoed ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
High Risk ◽  
Low Risk ◽  
Premalignant Lesions ◽  
High Risk Patients ◽  
European Guidelines ◽  
Progression Of Disease ◽  
Risk Patients ◽  
Progression Risk

Abstract Introduction Guidelines recommend endoscopy with biopsies to stratify patients with gastric premalignant lesions (GPL) to high and low progression risk. High-risk patients are recommended to undergo surveillance. We aimed to assess the accuracy of guideline recommendations to identify low-risk patients, who can safely be discharged from surveillance. Methods This study includes patients with GPL. Patients underwent at least two endoscopies with an interval of 1–6 years. Patients were defined ‘low risk’ if they fulfilled requirements for discharge, and ‘high risk’ if they fulfilled requirements for surveillance, according to European guidelines (MAPS-2012, updated MAPS-2019, BSG). Patients defined ‘low risk’ with progression of disease during follow-up (FU) were considered ‘misclassified’ as low risk. Results 334 patients (median age 60 years IQR11; 48.7% male) were included and followed for a median of 48 months. At baseline, 181/334 (54%) patients were defined low risk. Of these, 32.6% were ‘misclassified’, showing progression of disease during FU. If MAPS-2019 were followed, 169/334 (51%) patients were defined low risk, of which 32.5% were ‘misclassified’. If BSG were followed, 174/334 (51%) patients were defined low risk, of which 32.2% were ‘misclassified’. Seven patients developed gastric cancer (GC) or dysplasia, four patients were ‘misclassified’ based on MAPS-2012 and three on MAPS-2019 and BSG. By performing one additional endoscopy 72.9% (95% CI 62.4–83.3) of high-risk patients and all patients who developed GC or dysplasia were identified. Conclusion One-third of patients that would have been discharged from GC surveillance, appeared to be ‘misclassified’ as low risk. One additional endoscopy will reduce this risk by 70%.

Sign in / Sign up

Export Citation Format

Share Document